Skip to main content
. 2022 Dec 1;9:1058235. doi: 10.3389/fmed.2022.1058235

FIGURE 4.

FIGURE 4

Kaplan–Meier of 28-day mortality after Adrecizumab/placebo infusion, based on a combined stratification approach implementing a cDPP3 <50 ng/mL as well as a treatment time <8.5 h after diagnosis of shock. Both Adrecizumab dosing groups were combined. Crosses represent censored patients.